Constitutive Knockout

Mdr1a/b Constitutive Knockout Mouse Model

FVB Background

  • Model #
  • Genotype
  • Nomenclature
  • 1487-F
    FVB.129P2-Abcb1atm1BorAbcb1btm1Bor N12
  • 1487-M
    FVB.129P2-Abcb1atm1BorAbcb1btm1Bor N12
  • Carries a disruption of multi-drug resistance genes Abcb1a (ATP-binding cassette, sub-family B (MDR/TAP), member 1A, a.k.a. Mdr1a) and Abcb1b (ATP-binding cassette, sub-family B (MDR/TAP), member 1B, a.k.a Mdr1b) encoding p-glycoprotein 3 and p-glycoprotein 1, respectively
  • Mdr1a protein is normally expressed actively in the intestine and at the blood-brain and blood-testis barriers
  • Mdr1b protein is normally highly expressed in the adrenal gland, pregnant uterus and ovaries
  • These p-glycoproteins actively extrude a wide range of drugs from cells and can confer multi-drug resistance to tumor cells
  • Lack the protective function of p-glycoproteins and exhibits a functional deficiency in the blood-brain barrier
  • Useful in a wide range of central nervous system research including neurotoxicology, drug transport, oral bioavailability and multi-drug resistance studies
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Genetic Background:

FVB Background


The Mdr1a/b mouse was developed in the laboratory of Alfred Schinkel of the Netherlands Cancer Institute. The model was created through sequential targeting of the Abcb1a and Abcb1b genes in E14 ES cells. Resultant chimeras were backcrossed to FVB/N for seven (N7) generations. Taconic received stock in August 1997. The mice were then backcrossed five more generations (N12) to FVB/N. The colony is maintained by mating doubly homozygous mice.


Wild type for Nnt mutation; carries Pde6brd1 mutation





Initial Publication:

Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA, 94(8):4028-4033.

Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions for Taconic Models, Products and Services and the following terms of use:
  • Title to these Models and biological materials derived from them remains with Taconic.
  • The Models will be used for research purposes only.
  • The Models will not be bred or cross-bred except to obtain embryos or fetuses required for research purposes unless additional rights have been granted in writing by Taconic.
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Non-profit purchasers may not use this Model and/or biological materials derived from it in sponsored research or contract research studies unless it is purchased at the for-profit price.

Welcome! Tell us a little about yourself